Showing results (71-80 of 76) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.Blood|January 6, 2026
Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemiaHartmut Döhner, Daniela Späth, Maral Saadati, et al.Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.Nature Genetics|November 8, 2016
The genomic landscape of core-binding factor acute myeloid leukemiasZachary J Faber, Xiang Chen, Amanda Larson Gedman, et al.Pageof 8